CCT241533 was developed by Cancer Research UK, with an oral bioavailability of 38 to 54%, and preliminary pharmacokinetic/pharmacodynamic studies demonstrate that it is well tolerated in mouse studies and shows efficacy in a tumor xenograft model (www.cancerresearchhorizons.com/licensing-opportunities/chk2-inhibitor-programme). This evidence concerns the gene CHEK2 and neoplasm.